http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-200605879-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-267
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-267
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06
filingDate 2005-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c0b6b7b01e10821994f74279d248522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3b8016ab1f2fa4bddd6798741347ea8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd2610f53f3758d6d739d69c805b3852
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76510c15a5e52be1db3f6c70ea52216d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5443fd31846ad15181c7bd6bc573305
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb279e9e6f3b27206cdfcb8b9380f5bd
publicationDate 2006-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber TW-200605879-A
titleOfInvention Pyrrolidinyl derivatives as 11-β hydroxysteroid dehydrogenase inhibitors
abstract The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1 or 2; L represents a C1-3alkyl linker optionally substituted with one or two substituents selected from C1-4alkyl, C1-3alkyloxy-C1-4alkyl-, hydioxy-C1-4alkyl, hydroxy, C1-3alkyloxy- or phenyl-C1-4alkyl; M represents a direct bond or a C1-3alkyl linker optionally substituted with one or two substituents selected from hydroxy, C1-4alkyl or C1-4alkyloxy; R1 and R2 each independently represent hydrogen, halo, cyano, hydroxy, C1-4alkyl optionally substituted with halo, C1-4alkyloxy- optionally substituted with one or where possible two or three substituents selected from hydroxy, Ar1 and halo; or R1 and R2 taken together with the phenyl ring to which they are attached form naphtyl or 1,3-benzodioxolyl, wherein said naphtyl or 1,3-benzodioxolyl are optionally substituted with halo; R3 represents hydrogen, halo, C1-4alkyl, C1-4alkyloxy-, cyano or hydroxy; R4 represents hydrogen, halo, C1-4alkyl, C1-4alkyloxy-, cyano or hydroxy; R5 represents hydrogen, C1-4alkyl or Ar2-C1-4alky-; R6 represents hydrogen, halo, C1-4alkyl or C1-4alkyoxy-; Ar1 and Ar2 each independently represent phenyl or naphtyl wherein said phenyl and naphtyl are optionally substituted with C1-4alkyl, C1-4alkyloxy-, or phenyl-C1-4alkyl; for use as a medicine.
priorityDate 2004-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454973655

Total number of triples: 35.